BACKGROUND: Oxidation of LDL produces a series of biologically active, oxidized lipids. Among them, isoprostanes, and in particular iPF(2alpha)-III, seem to be crucial in mediating some of the key cellular events seen in myocardial ischemia-reperfusion injury. METHODS AND RESULTS: Minimally modified LDL (MM-LDL) triggers a dose-dependent, very rapid neutrophil adhesion to human fibrinogen. Rapid adhesion triggering correlates with degree of LDL oxidation and accumulation of isoprostanes. Isoprostanes accumulated in MM-LDL are major determinants of the proadhesive effect of oxidized LDL, as shown by experiments of receptor functional deletion. Moreover, evidence is provided of expression on human neutrophils of a biological active isoprostane receptor distinct from the classical thromboxane A2 receptor. CONCLUSIONS: These data suggest that isoprostanes are major contributors to the proadhesive effect induced by MM-LDL on neutrophils and provide additional evidence for the involvement of isoprostanes in the pathogenesis of myocardial ischemia/reperfusion injury.
BACKGROUND: Oxidation of LDL produces a series of biologically active, oxidized lipids. Among them, isoprostanes, and in particular iPF(2alpha)-III, seem to be crucial in mediating some of the key cellular events seen in myocardial ischemia-reperfusion injury. METHODS AND RESULTS: Minimally modified LDL (MM-LDL) triggers a dose-dependent, very rapid neutrophil adhesion to humanfibrinogen. Rapid adhesion triggering correlates with degree of LDL oxidation and accumulation of isoprostanes. Isoprostanes accumulated in MM-LDL are major determinants of the proadhesive effect of oxidized LDL, as shown by experiments of receptor functional deletion. Moreover, evidence is provided of expression on human neutrophils of a biological active isoprostane receptor distinct from the classical thromboxane A2 receptor. CONCLUSIONS: These data suggest that isoprostanes are major contributors to the proadhesive effect induced by MM-LDL on neutrophils and provide additional evidence for the involvement of isoprostanes in the pathogenesis of myocardial ischemia/reperfusion injury.
Authors: Giampaolo Niccoli; Andrea Celestini; Camilla Calvieri; Nicola Cosentino; Elena Falcioni; Roberto Carnevale; Cristina Nocella; Francesco Fracassi; Marco Roberto; Roberta P Antonazzo; Pasquale Pignatelli; Filippo Crea; Francesco Violi Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-09-05
Authors: Marzena Ratajczak; Damian Skrypnik; Paweł Bogdański; Edyta Mądry; Jarosław Walkowiak; Monika Szulińska; Janusz Maciaszek; Matylda Kręgielska-Narożna; Joanna Karolkiewicz Journal: Int J Environ Res Public Health Date: 2019-11-05 Impact factor: 3.390
Authors: Georgios Louloudis; Samuele Ambrosini; Francesco Paneni; Giovanni G Camici; Dietmar Benke; Jan Klohs Journal: Front Cardiovasc Med Date: 2021-09-22
Authors: Ingrid Wiswedel; Daniela Peter; Andreas Gardemann; Francesco Carluccio; Hannelore Hampl; Werner Siems Journal: Biomark Insights Date: 2008-05-27